HER2-Positive Metastatic Breast Cancer Clinical Trial
Official title:
A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti−PD-L1 Antibody) in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer
This is a Phase Ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without docetaxel) or atezolizumab and trastuzumab emtansine in participants with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) and locally advanced early breast cancer (EBC), and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06278870 -
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT04692831 -
Testing a New Imaging Agent to Identify Cancer
|
Phase 1 | |
| Recruiting |
NCT04385563 -
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
|
Phase 3 | |
| Terminated |
NCT04778982 -
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
|
||
| Active, not recruiting |
NCT03417544 -
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
|
Phase 2 | |
| Recruiting |
NCT04319757 -
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05188495 -
Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab
|
||
| Recruiting |
NCT05583110 -
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT06298084 -
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05650879 -
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03979339 -
Feasibility of a New Technology for Isolating Circulating Tumour Cells
|
N/A | |
| Recruiting |
NCT05042791 -
A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases
|
Phase 2 | |
| Active, not recruiting |
NCT05555251 -
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04602117 -
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05959291 -
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
|
N/A | |
| Recruiting |
NCT06299852 -
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
|
N/A | |
| Completed |
NCT06305702 -
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
|
||
| Recruiting |
NCT05868226 -
PRE-I-SPY Phase I/Ib Oncology Platform Program
|
Phase 1 | |
| Recruiting |
NCT05800275 -
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
|
Phase 2 | |
| Recruiting |
NCT05036252 -
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
|